US 11,851,445 B2
Compounds and uses thereof
Sabine K. Ruppel, Cambridge, MA (US); Zhaoxia Yang, Belmont, MA (US); Jason T. Lowe, East Bridgewater, MA (US); and Johannes H. Voigt, Cambridge, MA (US)
Assigned to FOGHORN THERAPEUTICS INC., Cambridge, MA (US)
Filed by Foghorn Therapeutics Inc., Cambridge, MA (US)
Filed on Jan. 29, 2021, as Appl. No. 17/162,608.
Claims priority of provisional application 63/058,121, filed on Jul. 29, 2020.
Claims priority of provisional application 62/967,524, filed on Jan. 29, 2020.
Prior Publication US 2021/0230190 A1, Jul. 29, 2021
Int. Cl. C07D 519/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); C07D 471/10 (2006.01); A61K 31/4545 (2006.01); A61K 31/12 (2006.01)
CPC C07D 519/00 (2013.01) [A61P 35/00 (2018.01)] 6 Claims
 
1. A compound having the structure:

OG Complex Work Unit Chemistry
or

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.